Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics targeting neurodegenerative disorders. Cognito’s lead digital therapeutic is a breakthrough designated device with disease-modifying potential for the treatment of Alzheimer’s. Cognito is based in Cambridge, MA.